Certara (NASDAQ:CERT) Shares Gap Up to $10.70

Certara, Inc. (NASDAQ:CERT) gapped up before the market opened on Friday . The stock had previously closed at $10.70, but opened at $11.59. Certara shares last traded at $11.74, with a volume of 140,900 shares.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. JMP Securities reiterated a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Friday. Barclays reduced their price target on Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. KeyCorp dropped their price objective on shares of Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Finally, Robert W. Baird cut their target price on shares of Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Six research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $17.79.

Certara Stock Performance

The stock has a 50 day moving average of $12.82 and a 200 day moving average of $15.16. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of -30.18, a price-to-earnings-growth ratio of 5.17 and a beta of 1.49. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The firm had revenue of $93.31 million during the quarter, compared to analyst estimates of $96.01 million. During the same quarter last year, the firm posted $0.10 EPS. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. As a group, analysts predict that Certara, Inc. will post 0.27 EPS for the current year.

Insider Buying and Selling at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the transaction, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 2.39% of the company’s stock.

Institutional Trading of Certara

Large investors have recently modified their holdings of the stock. Pineridge Advisors LLC acquired a new stake in Certara in the fourth quarter worth $28,000. Blue Trust Inc. acquired a new stake in shares of Certara in the 2nd quarter valued at about $26,000. Innealta Capital LLC bought a new stake in Certara in the 2nd quarter valued at about $36,000. YHB Investment Advisors Inc. acquired a new position in Certara during the 1st quarter worth approximately $47,000. Finally, Intech Investment Management LLC acquired a new position in Certara during the 2nd quarter worth approximately $152,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.